, Volume 28, Issue 8, pp 823-824
Date: 12 Mar 2008

Leukocytapheresis for the treatment of refractory Henoch-Schönlein purpura resistant to both prednisolone and intravenous immunoglobulin therapy

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Leukocytapheresis (LCAP) has been reported to be effective for the treatment of various autoimmune disorders [13]. Recently, we encountered the dramatic efficacy of LCAP in a Japanese girl with refractory Henoch-Schönlein purpura (HSP) resistant to combined prednisolone (PDN) plus intravenous immunoglobulin (IVIG) administration. Although IVIG has been reported to be an effective treatment of choice for selected patients with refractory HSP [4], this was not the case in our patient. Thus, this case report may lend further support to the efficacy of LCAP for selected patients with refractory HSP.

A 5-year-old Japanese girl was admitted to a regional hospital with a generalized purpuric rash associated with severe abdominal pain. Subsequently, she developed bloody diarrhea and waxing aggravation of the purpuric rash. The blood coagulation factor XIII (F XIII) activity was decreased to 20% (normal range > 70%) and serum level of C-reactive protein (CRP) was increased to 2.2 mg dl−1. Thus, ...